TRENTON, NJ (June 7, 2010) – BioNJ, New Jersey’s trade association for the biotechnology industry, will hold its 2010 BioPartnering Conference on June 14 and 15 at the Westin Princeton at Forrestal Village, in Princeton, NJ. New Jersey’s only biopartnering conference, the two-day meeting will provide a valuable opportunity for biotechnology and pharmaceutical companies located in New Jersey and beyond to discuss partnerships, licensing agreements and other collaborative efforts, and will include keynote speakers from Johnson & Johnson, Merck & Co., Inc, Pfizer, sanofi-aventis us, and Defined Health.
The conference will include partnering sessions, company presentations and speaker sessions with top-level executives from leading biotechnology, pharmaceutical and research industries. Participants will have an opportunity to showcase their companies, meet potential funders, and network with other biotechnology companies from New Jersey and around the world.
Debbie Hart, president of BioNJ, says that the opportunities available at the conference will have far-reaching effects.
“This is a significant opportunity for New Jersey’s biotechnology firms to network with other companies from New Jersey and around the world,” she said. “We’re confident that this conference will result in new partnerships and collaborations, which will continue to spur the growth of the biotechnology industry in New Jersey, and beyond.”
A number of companies have signed up to showcase their companies in 15-minute presentations, scheduled throughout both days. This will allow companies to exhibit their latest research and development to potential sponsors and partners among the conference’s attendees. Partnering sessions, also held both days, will give large and smaller companies a chance to network.
The dinner keynote speaker on June 14 will be Dr. Paul Chew, Chief Scientific Officer and Chief Medical Officer of sanofi-aventis US. Barbara Yanni, Vice President and Chief Licensing Officer of Merck & Co., Inc., will provide the opening keynote on Monday. Edward Saltzman, President of Defined Health, a leading consulting firm for the pharmaceutical and biotechnology industries, will serve as the luncheon keynote on June 14.
On Tuesday, June 15, Adam Keeney, Ph.D., Vice President for Business Development at Johnson & Johnson, will provide the keynote at the closing luncheon. Earlier on Tuesday, Cynthia Green, Ph.D., Director of Worldwide Business Development Strategy & Innovation at Pfizer will present the keynote for the morning plenary session.
Another highlight of the conference is a June 14 afternoon panel hosted by the N.J. Chapter of the Licensing Executives Society, a 5,000-member organization in the U.S. and Canada. The panel will be moderated by Saltzman, and will consist of Pamela Demain of Merck & Co., Christine Fischette, Ph.D. of Enzo Therapeutics, Inc., and Marc Simon of the Williver Group.
Experts in Business Development working for venture capital firms, biotechnology and pharmaceutical companies will convene on the morning of June 15 for a panel entitled Business Development Strategies. Moderated by Raymond Thek of Lowenstein Sandler; the panel includes Morgan Conn, Ph.D. of PTC Therapeutics, Mark Dennis of Daiichi Sankyo, Inc., Karen LaRochelle of Bristol-Myers Squibb and Paul Barone of Celldex Therapeutics, Inc.
With over 265 member companies, BioNJ is singularly focused on the growth and prosperity of New Jersey’ bioscience cluster. Founded in 1994 by New Jersey bioscience industry CEOs, BioNJ serves as the voice of bioscience companies located in New Jersey, seeks to advance their economic growth and development and works to encourage new and established companies from around the world to locate here. BioNJ represents companies engaged in biopharmaceutical, biomedical, bioagricultural and bioremedial endeavors.
Director of Public Affairs